FORM S-3
As filed with the Securities and Exchange Commission on
March 19, 2008
Registration Statement No.
333-
UNITED STATES SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
Form S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
MARSHALL EDWARDS,
INC.
(Exact name of Registrant as
specified in its charter)
|
|
|
Delaware
(State or other jurisdiction
of
incorporation or organization)
|
|
51-0407811
(I.R.S. Employer
Identification Number)
|
140 Wicks Road
North Ryde NSW 2113
Australia
(011) 61 2 8877
6196
(Address, including zip code,
and telephone number, including area code, of registrants
principal executive offices)
The Corporation
Trust Company
The Corporation
Trust Center
1209 Orange Street
Wilmington, Delaware
19801
(302) 658-7581
(Name, address, including zip
code, and telephone number, including area code of agent for
service)
with
copies to:
|
|
|
Christopher Naughton
President & Chief Executive Officer
Marshall Edwards, Inc.
140 Wicks Road
North Ryde NSW 2113 Australia
(011) 61 2 8877 6196
|
|
Howard A. Kenny, Esq.
Morgan, Lewis & Bockius LLP
101 Park Avenue
New York, New York 10178
(212) 309-6000
|
Approximate date of commencement of proposed sale to the public:
From time to time after this Registration Statement becomes
effective.
If the only securities being registered on this form are being
offered pursuant to dividend or interest reinvestment plans,
please check the following
box. o
If any of the securities being registered on this form are to be
offered on a delayed or continuous basis pursuant to
Rule 415 under the Securities Act of 1933, other than
securities offered only in connection with dividend or interest
reinvestment plans, check the following
box. þ
If this form is filed to register additional securities for an
offering pursuant to Rule 462(b) under the Securities Act
of 1933, please check the following box and list the Securities
Act registration statement number of the earlier effective
registration statement for the same
offering. o
If this form is a post-effective amendment filed pursuant to
Rule 462(c) under the Securities Act of 1933, check the
following box and list the Securities Act registration statement
number of the earlier effective registration statement for the
same
offering. o
If this Form is a registration statement pursuant to General
Instruction I.D. or a post-effective amendment thereto that
shall become effective upon filing with the Commission pursuant
to Rule 462(e) under the Securities Act, check the
following
box. o
If this Form is a post-effective amendment to a registration
statement filed pursuant to General Instruction I.D. filed
to register additional securities or additional classes of
securities pursuant to Rule 413(b) under the Securities
Act, check the following
box. o
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated
filer, or a smaller reporting company. See the definitions of
large accelerated filer, accelerated
filer and smaller reporting company in Rule
12b-2 of the
Exchange Act. (Check one):
|
|
|
|
|
|
|
Large accelerated
filer o
|
|
Accelerated
filer o
|
|
Non-accelerated
filer þ
(Do not check if a smaller reporting company)
|
|
Smaller reporting
company o
|
CALCULATION OF REGISTRATION
FEE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proposed Maximum
|
|
|
Proposed Maximum
|
|
|
Amount of
|
Title of Each Class of
|
|
|
Amount to be
|
|
|
Offering Price per
|
|
|
Aggregate
|
|
|
Registration
|
Securities to be Registered
|
|
|
Registered(1)
|
|
|
Unit(2)
|
|
|
Offering Price(3)
|
|
|
Fee(3)
|
Common Stock, $0.00000002 par value(4)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred Stock, $0.01 par value(5)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants(6)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
$
|
75,000,000
|
|
|
|
|
100
|
%
|
|
|
$
|
75,000,000
|
|
|
|
$
|
2,947.50
|
(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
An indeterminate aggregate initial
offering price or number of the securities of each identified
class is being registered as may be sold from time to time at
indeterminate prices, with any initial offering price not to
exceed $75,000,000 or the equivalent thereof in one or more
currencies.
|
|
(2)
|
|
The proposed maximum aggregate
offering price of each class of securities will be determined
from time to time by the registrant in connection with the
issuance by the registrant of the securities registered
hereunder and is not specified as to each class of securities
pursuant to General Instruction II. D of
Form S-3
under the Securities Act of 1933
|
|
(3)
|
|
Estimated solely for the purpose of
calculating the registration fee pursuant to Rule 457(o)
under the Securities Act of 1933. In no event will the aggregate
offering price of all securities sold by the registrant from
time to time pursuant to this Registration Statement exceed
$75,000,000 or the equivalent thereof in one or more other
currencies.
|
|
(4)
|
|
Subject to footnote (2), there is
being registered hereunder an indeterminate number of shares of
common stock as may from time to time be sold at indeterminate
prices hereunder, and an indeterminate number of shares of
common stock as may from time to time be issued upon conversion
of shares of preferred stock and upon exercise of warrants,
which may be sold hereunder. Pursuant to Rule 416 under the
Securities Act of 1933, to the extent additional common shares
may be issued or issuable as a result of a stock split or other
distribution declared at any time by the registrants board
of directors while this Registration Statement is in effect,
this Registration Statement is hereby deemed to cover all of
such additional shares of common stock.
|
|
(5)
|
|
Subject to footnote (2), there is
being registered hereunder an indeterminate number of shares of
preferred stock as may from time to time be sold at
indeterminate prices hereunder, and an indeterminate number of
shares of preferred stock as may from time to time be issued
upon exercise of warrants, which may be sold hereunder.
|
|
(6)
|
|
Subject to footnote (2), there is
being registered hereunder an indeterminate number of warrants
as may from time to time be sold at indeterminate prices
representing rights to purchase certain of the shares of common
stock and shares of preferred stock registered hereunder.
|
The Registrant hereby amends this Registration Statement on
such date or dates as may be necessary to delay its effective
date until the Registrant shall file a further amendment which
specifically states that this Registration Statement shall
thereafter become effective in accordance with Section 8(a)
of the Securities Act of 1933 or until the Registration
Statement shall become effective on such date as the Commission,
acting pursuant to said Section 8(a), may determine.
The
information contained in this prospectus is not complete and may
be changed. We may not sell these securities until the
registration statement filed with the Securities and Exchange
Commission is effective. This prospectus it not an offer to sell
these securities and it is not soliciting an offer to buy these
securities in any state where the offer and sale is not
permitted.
|
SUBJECT TO COMPLETION, DATED
MARCH 19, 2008
PROSPECTUS
$75,000,000
MARSHALL EDWARDS,
INC.
Common Stock
Preferred Stock
Warrants
We may offer our common stock, preferred stock and warrants to
purchase our common stock or preferred stock. Our common stock
is quoted on the Nasdaq Global Market under the symbol
MSHL.
We may offer these securities at prices and on terms to be set
forth in one or more supplements to this prospectus. These
securities may be offered directly, through agents on our behalf
or through underwriters or dealers.
Our common stock is traded on the NASDAQ Global Market under the
symbol MSHL. On March 17, 2008, the closing
price of our common stock on the NASDAQ Global Market was $2.06
per share. The market value of our outstanding common equity
held by non-affiliates on March 17, 2008 was $39,871,172.
We have not offered any securities pursuant to General
Instruction I.B.6. of
Form S-3
during the 12 calendar months prior to and including the date
hereof.
An investment in our securities involves significant risks.
You should carefully consider the risk factors beginning on
page 3 of this prospectus before investing in our
securities.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these
securities or passed upon the adequacy of this prospectus. Any
representation to the contrary is a criminal offense.
The date of this prospectus is March , 2008.
ABOUT
THIS PROSPECTUS
Unless we have indicated otherwise, references in this
prospectus to Marshall Edwards, we,
us and our or similar terms are to
Marshall Edwards, Inc., a Delaware corporation, and its
consolidated subsidiary, Marshall Edwards Pty Limited.
References in this prospectus to Novogen refer to
Novogen Limited and its consolidated subsidiaries, other than
Marshall Edwards, Inc. and its subsidiary. References in this
prospectus to FDA refer to the United States Food
and Drug Administration.
This prospectus is part of a registration statement that we
filed with the Securities and Exchange Commission, or SEC,
utilizing a shelf registration statement. This
prospectus provides you with a general description of the
securities we may offer. We will describe the specific terms of
those securities, as necessary, in supplements that we attach to
this prospectus for each offering. Each supplement will also
contain specific information about the terms of the offering it
describes. The supplements may also add, update or change
information contained in this prospectus. In addition, as we
describe in the section entitled Where You Can Find More
Information, we have filed and plan to continue to file
other documents with the SEC that contain information about us.
Before you decide whether to invest in our securities, you
should read this prospectus, the supplement that further
describes the offering of those securities and the information
we otherwise file with the SEC.
The registration statement that contains this prospectus,
including the exhibits to the registration statement, contains
additional information about us and the securities being offered
under this prospectus. You should read the registration
statement and the accompanying exhibits for further information.
The registration statement and exhibits can be read and are
available to the public over the Internet at the SECs
website at http: //www.sec.gov.
You should rely only on the information contained or
incorporated by reference in this prospectus and in any
prospectus supplement. We have not authorized any person to
provide any information or make any statement that differs from
what is contained in this prospectus. If any person does make a
statement that differs from what is in this prospectus, you
should not rely on it. This prospectus is not an offer to sell,
nor is it a solicitation of an offer to buy, these securities in
any state in which the offer or sale is not permitted. The
information in this prospectus is accurate as of its date, but
the information may change after that date. You should not
assume that the information in this prospectus is accurate as of
any date after its date.
i
SUMMARY
Company
Overview
We are a developmental stage pharmaceutical company,
incorporated on December 1, 2000 as a wholly-owned
subsidiary of Novogen Limited, an Australian company.
Novogens ordinary shares trade on the Australian
Securities Exchange under the symbol NRT and
American Depositary Receipts trade in the United States under
the symbol NVGN on the Nasdaq Global Market. Novogen
currently owns approximately 71.9% of our outstanding common
stock.
We commenced operations in May 2002 and our business purpose is
the development and commercialization of drugs for the treatment
of cancer. We are presently engaged in the clinical development
and commercialization of a drug candidate called phenoxodiol
which we have licensed from Novogen. We believe that phenoxodiol
may have broad application against a wide range of cancers.
Phenoxodiol appears to target a number of key components
involved in cancer cell survival and proliferation based on the
emerging field of signal transduction regulation, with little or
no effect on normal cells detected in pre-clinical testing. We
have also licensed two other anti-cancer compounds, triphendiol
(formally NV-196) and NV-143, from Novogen.
Our strategy is to undertake further clinical development and
testing of phenoxodiol, focusing on those therapeutic
indications that will expedite drug marketing approval by
regulatory bodies, leading to phenoxodiols
commercialization and wide scale distribution. We also plan to
develop triphendiol and NV-143 for therapeutic indications not
currently targeted by phenoxodiol.
Pre-clinical testing has shown phenoxodiol to have broad
anti-cancer action against a range of human cancer cell lines,
including prostate, ovarian and squamous cell carcinoma.
Phenoxodiol commenced Phase I clinical studies in Australia in
2000, and the FDA granted phenoxodiol fast tract status for
treatment of patients with recurrent late stage ovarian cancer
that is resistant or refractory to platinums and taxanes in
2004, and for treatment of patients with hormone refractory
prostate cancer, which is prostate cancer that grows and is not
inhibited by hormone therapy, in 2005.
The immediate clinical development priority for phenoxodiol is
to focus on three forms of cancer ovarian cancer,
prostate adenocarcinoma and squamous cell carcinoma of the
cervix and vagina.
In ovarian cancer, we are testing the ability of phenoxodiol to
overcome chemotherapy drug resistance mechanisms, reversing
resistance to platinums and taxanes in particular. This is an
international Phase III pivotal study (known as OVATURE) in
patients who have become resistant or refractory to at least two
lines of platinum therapy, where phenoxodiol is being tested in
combination with weekly carboplatin to delay tumor progression
as measured by progression-free survival.
We are also developing phenoxodiol for use in squamous cell
carcinoma of the cervix, vagina and vulva. A Phase I study is
ongoing with a view to providing evidence of both a biological
and clinical effect in this aggressive form of cancer. A
positive outcome in the current study could lead to two
potential therapeutic indications: (i) the use of
phenoxodiol as a monotherapy in early-stage disease including
pre-malignant disease; and (ii) the use of phenoxodiol in
combination with standard drugs such as cisplatin for the
treatment of non-resectable disease.
Prostate cancer is the third tumor type of a number of tumors
which we believe are likely to be responsive to phenoxodiol
therapy. We have completed a Phase II study in advanced
hormone refractory disease in Australia and we are currently
conducting a Phase II study using phenoxodiol as first line
treatment in early stage disease at Yale Cancer Center and the
West Haven Veterans Administration Hospital Connecticut in the
United States. Both of these studies address areas of unmet
medical need in this common cancer.
For the OVATURE Phase III pivotal trial for ovarian cancer,
we completed a Special Protocol Assessment, or SPA, with FDA in
May 2006. The SPA process allows for FDA evaluation of a
clinical trial protocol that will form the basis of an efficacy
claim for a marketing application and provides a binding
agreement that the study design, including patient numbers,
clinical endpoints and analyses, are acceptable to the FDA. As a
fast track product candidate, phenoxodiol will be eligible for
accelerated approval and priority review of the marketing
application for this indication.
1
In May 2006, we and Novogen entered into a license agreement
pursuant to which Novogen granted to us, through Marshall
Edwards Pty Limited (MEPL), an exclusive, worldwide
non-transferable license under its patent and patent
applications and in its know how to conduct clinical trials,
commercialize and distribute the anti-cancer drug candidates,
triphendiol and NV-143.
Triphendiol is a synthetic investigational anti-cancer compound
developed by Novogen, based on an isoflavan ring structure.
Similar to phenoxodiol, triphendiol is a signal transduction
inhibitor. Preliminary screening studies conducted by Novogen
have identified triphendiol as a candidate for product
development showing a favorable in vitro toxicity profile
against normal cells and broad activity against cancer cells.
Triphendiol is currently in Phase I human testing in Australia
and is being developed initially in oral form for the treatment
of pancreatic and bile duct cancers.
NV-143 is currently in pre-clinical testing. Preliminary
screening studies have identified broad anti-cancer activity
against cancer cells representative of melanoma, glioma,
prostate, ovarian, breast and lung cancer. Moderate activity was
observed against colorectal cancer cells. NV-143 also exhibits
broadly acting chemo-sensitizing activity or the ability to
increase the sensitivity of cells to chemotherapeutic drugs that
are used to control the growth of cancer cells. The mechanisms
by which NV-143 elicits its anti-cancer/chemo-sensitizing effect
remain unresolved. NV-143 may initially be developed to target
the treatment of melanoma.
Recent
Developments
In January 2008, we announced that triphendiol had been granted
Orphan Drug status by the FDA for the treatment of pancreatic
cancer and for the treatment of cholagiocarcinoma or bile duct
cancer.
In February 2008, we announced that triphendiol had been granted
Orphan Drug status by the FDA for the treatment of Stage IIB
through Stage IV malignant melanoma.
An Orphan Drug refers to a product that is intended for use in a
disease or condition that affects fewer than 200,000 individuals
in the United States. A grant of Orphan Drug status provides
seven years of market exclusivity for the orphan indication
after approval by the FDA, as well as study design assistance
and eligibility for grant funding from the FDA during its
development. Triphendiol is in the early stages of clinical
development and we will need to conduct significant clinical
testing to prove safety and efficacy before marketing
applications may be filed with the FDA. There can be no
guarantee that triphendiol will ever receive marketing approval
by the FDA.
Our
Address and Telephone Number
Our principal executive office is located at 140 Wicks Road,
North Ryde NSW 2113, Australia and our telephone number is 011
61 2 8877 6196. Our Internet website address is
www.marshalledwardsinc.com. The information contained on our
website shall not be deemed to constitute a part of this
prospectus.
2
RISK
FACTORS
An investment in our securities involves a high degree of risk.
You should carefully consider the risks described below,
together with all other information contained in this prospectus
before deciding to purchase our securities. If any of the
following risks actually occur, our business, financial
condition or operating results may be harmed. In that case, the
trading price of our securities may decline and you may lose
part or all of your investment in our securities.
Risks
Related to Our Business
We
will need additional funds to complete the OVATURE
Phase III clinical trial for phenoxodiol and to progress
the clinical trial program for triphendiol and NV-143. The
actual amount of funds we will need will be determined by a
number of factors, some of which are beyond our
control.
The factors which will determine the actual amount of funds that
we will need to complete the OVATURE Phase III clinical
trial for phenoxodiol and to progress the clinical trial
programs for triphendiol and NV-143 may include the following:
|
|
|
|
|
the number of sites included in the trials;
|
|
|
|
the length of time required to enroll suitable patients;
|
|
|
|
the number of patients that participate in the trials and the
rate that they are recruited;
|
|
|
|
the number of treatment cycles patients complete while they are
enrolled in the trials; and
|
|
|
|
the efficacy and safety profile of the product.
|
If we are unable to obtain additional funds on favorable terms
we may be required to cease or reduce our operations. Also, if
we raise more funds by selling additional securities, the
ownership interests of holders of our securities will be diluted.
We may
not complete our OVATURE Phase clinical III trial on
schedule, or at all, or it may be conducted improperly, which
will delay or preclude FDA marketing approval and increase
costs.
The completion of our OVATURE Phase III clinical trial may
be delayed or terminated for many reasons, including, but not
limited to, if:
|
|
|
|
|
we are unable to identify and contract clinical trial sites and
clinical investigators at the rate we expect or those sites are
delayed from commencing patient recruitment due to regulatory
hospital ethics committee approvals or those investigators do
not perform to our anticipated patient recruitment schedule or
comply with the clinical trial protocol;
|
|
|
|
patients are not available to enroll at the rate we currently
expect, or trial sites are unable to recruit their target
patient numbers due to the strict inclusion criteria of the
OVATURE protocol which may reduce the patient pool available to
participate in the trial;
|
|
|
|
subjects experience an unacceptable rate or severity of adverse
side effects;
|
|
|
|
third party clinical investigators do not conduct the trial in
compliance with Good Clinical Practice and regulatory
requirements, or other third parties do not perform data
collection and analysis in a timely or accurate manner;
|
|
|
|
one or more Institutional Review Boards suspend or terminate the
trial at an investigational site, precludes enrollment of
additional subjects, or withdraws its approval of the
trial; or
|
|
|
|
one or more of our clinical investigators withdraws from our
trials or deviates from our approved protocol.
|
Our costs will increase if we have material delays in our
OVATURE pivotal trial, or if we are required to modify, suspend,
terminate or repeat it.
3
If the
data from our OVATURE Phase III clinical trial do not
demonstrate the safety and effectiveness of phenoxodiol to the
FDAs satisfaction, we will not receive FDA approval to
market phenoxodiol in the United States.
In 2004, the FDA granted phenoxodiol fast track status for
patients with recurrent late stage ovarian cancer that is
resistant or refractory to platinums and taxanes. More recently
we completed an SPA where the FDA reviewed and agreed with the
design of a Phase III study of phenoxodiol in combination
with carboplatin in women with platinum-resistant ovarian cancer
(ovarian cancer that does not respond to platinum based
anti-cancer agents such as cisplatin). If the FDA concludes,
using agreed clinical endpoints, that the data from our pivotal
clinical trial have failed to demonstrate the safety and
effectiveness of phenoxodiol to the satisfaction of the FDA, we
will not receive FDA approval to market phenoxodiol in the
United States. We cannot assure you that the results of our
Phase III trial will be successful.
The
third-party manufacturers that we rely upon for the production
of phenoxodiol for our clinical trials and for future commercial
quantities, may not be in compliance with FDA regulatory
requirements.
The conduct of our clinical trials and approval of our marketing
application for phenoxodiol may be delayed or adversely affected
if the third-party manufacturers that we rely upon for the
production of phenoxodiol fail to comply with FDAs
regulatory requirements for current Good Manufacturing
Practices, or cGMP. The FDA requires drug manufacturers to
establish and maintain quality control procedures for
manufacturing, processing and holding drugs and investigational
products, and products must be manufactured in accordance with
defined specifications. The failure of contract manufacturers to
supply investigational product in compliance with the defined
specifications for phenoxodiol may delay the completion of our
clinical trials. As part of the pre-market approval process, the
manufacturer will be inspected by the FDA to ensure compliance
with cGMP. The failure of contract manufacturers to comply with
applicable regulations may result in a delay or prevent approval
of our marketing application.
If we
do not receive marketing approval, our commercial prospects for
phenoxodiol will be impaired.
Clinical trials have a high risk of failure. A number of
companies in the pharmaceutical industry, including
biotechnology companies, have suffered significant setbacks in
advanced clinical trials, even after achieving promising results
in earlier trials. If our clinical trials are unsuccessful, our
prospects for commercializing phenoxodiol will be impaired and
we may be required to cease or reduce our operations. This will
have a significant impact on the trading price of our securities.
Final
approval by regulatory authorities of our drug candidates for
commercial use may be delayed, limited or prevented, any of
which would adversely affect our ability to generate operating
revenues.
Any of the following factors may serve to delay, limit or
prevent the final approval by regulatory authorities of our drug
candidates for commercial use:
|
|
|
|
|
triphendiol and NV-143 are in the early stages of clinical
development and we will need to conduct significant clinical
testing to prove safety and efficacy before applications for
marketing can be filed with the FDA, or with the regulatory
authorities of other countries;
|
|
|
|
data obtained from pre-clinical and clinical tests can be
interpreted in different ways, which could delay, limit or
prevent regulatory approval;
|
|
|
|
development and testing of product formulation, including
identification of suitable excipients, or chemical additives
intended to facilitate delivery of our drug candidates;
|
|
|
|
it may take us many years to complete the testing of other drug
candidates, and failure can occur at any stage of this
process; and
|
|
|
|
negative or inconclusive results or adverse medical events
during a clinical trial could cause us to delay or terminate our
development efforts.
|
4
While we have not encountered any material delays or adverse
events from the factors described above to date, we cannot
assure you that such delays or adverse events will not be
encountered in the future.
We
have a limited operating history, and we are likely to incur
operating losses for the foreseeable future.
You should consider our prospects in light of the risks and
difficulties frequently encountered by early stage and
developmental companies. Although we were incorporated in
December 2000, we have only been in operation since May 2002. We
have incurred net losses of $44,998,000 since our inception
through December 31, 2007, including net losses of
$13,820,000, $7,386,000 and $6,421,000 for the years ended
June 30, 2007, 2006 and 2005, respectively. We anticipate
that we will incur operating losses and negative operating cash
flow for the foreseeable future. We have not yet commercialized
any drug candidates and cannot be sure that we will ever be able
to do so, or that we may ever become profitable. We have
expanded our clinical trials significantly with the commencement
of the OVATURE Phase III clinical trial, which will result
in increasing losses and we may continue to incur substantial
losses in the future even if we begin to generate revenues from
the distribution and sale of phenoxodiol.
We may
not be able to establish the strategic partnerships necessary to
develop, market and distribute phenoxodiol.
A key part of our business plan is to establish relationships
with strategic partners. We must successfully contract with
third parties to package, market and distribute phenoxodiol. We
have not yet established any strategic partnerships. Potential
partners may not wish to enter into agreements with us due to
Novogens current equity position as our majority
stockholder or our contractual relationships with Novogen.
Similarly, potential partners may be discouraged by our limited
operating history. Additionally, our relative attractiveness to
potential partners and consequently, our ability to negotiate
acceptable terms in any partnership agreement, will be affected
by the results of our clinical program. For example, if
phenoxodiol is shown to have high efficacy against a broad range
of cancers, we may generate greater interest from potential
partners than if phenoxodiol is demonstrated to be less
effective or applicable to a narrower range of cancers. There is
no assurance that we will be able to negotiate commercially
acceptable licensing or other agreements for the future
exploitation of phenoxodiol, including the continued clinical
development, manufacture or marketing of phenoxodiol. If we are
unable to successfully contract for these services, or if
arrangements for these services are terminated, we may have to
delay our commercialization program for phenoxodiol which will
adversely affect our ability to generate operating revenues.
We
have not yet submitted an Investigational New Drug Application,
or IND, for triphendiol or NV-143 product candidates with the
FDA and until an IND becomes effective, we will not be able to
perform human clinical trials in the United
States.
Although we have conducted two Phase I clinical trials of
triphendiol in Australia, we have not yet submitted an IND to
the FDA. NV-143 has not yet commenced clinical trials in humans.
Until an IND becomes effective, we will not be able to perform
human clinical trials of our triphendiol or NV-143 product
candidates in the United States. Approval to begin clinical
testing in the United States requires submission of:
(i) adequate information on the safety and manufacturing of
triphendiol or NV-143 to assure the proper identification
quality, purity and strength of the investigational product,
(ii) summary of pharmacological and toxicological effects,
pharmacokinetics (how the drug is absorbed and metabolised) and
biological disposition in animals, (iii) the proposed
protocol for any planned clinical study, and (iv) a brief
description of the overall plan for investigating the product.
Although we are preparing an IND for triphendiol for submission
to the FDA, we do not know whether or when the IND will become
effective.
Our
commercial opportunity will be reduced or eliminated if
competitors develop and market products that are more effective,
have fewer side effects or are less expensive than
phenoxodiol.
The development of phenoxodiol and other drug candidates is
highly competitive. A number of other companies have products or
drug candidates in various stages of pre-clinical or clinical
development that are intended for the same therapeutic
indications for which phenoxodiol is being developed. Some of
these potential competing drugs are further advanced in
development than phenoxodiol and may be commercialized sooner.
Even
5
if we are successful in developing effective drugs, phenoxodiol
may not compete successfully with products produced by our
competitors.
Our competitors include pharmaceutical companies and
biotechnology companies, as well as universities and public and
private research institutions. In addition, companies active in
different but related fields represent substantial competition
for us. Many of our competitors developing oncology drugs have
significantly greater capital resources, larger research and
development staffs and facilities and greater experience in drug
development, regulation, manufacturing and marketing than us.
These organizations also compete with Novogen, our services
provider, to recruit qualified personnel, and with us to attract
partners for joint ventures and to license technologies that are
competitive with ours. As a result, our competitors may be able
to more easily develop technologies and products that would
render our technologies or our drug candidates obsolete or
non-competitive.
We
have no direct control over the costs of manufacturing
phenoxodiol, triphendiol or NV-143 and increases in these costs
would increase the costs of conducting clinical trials and could
adversely affect future profitability if these costs increase
significantly.
We do not intend to manufacture phenoxodiol, triphendiol or
NV-143 ourselves and we will be relying on third parties for our
supplies of phenoxodiol both for clinical trials and for
commercial quantities in the future. Novogen, has taken the
strategic decision not to manufacture on a large scale Active
Pharmaceutical Ingredients, or API, for cancer drugs, including
phenoxodiol, as these can be more economically supplied by third
parties with particular expertise in this area. The contract
facilities that have been identified are registered with the
FDA, have a track record of large scale API manufacture and have
already invested in capital and equipment. We have completed the
novation to MEPL of contracts that Novogen had entered into with
third parties to validate the developed scalable manufacturing
method to ensure that sufficient quantities of phenoxodiol can
be manufactured in compliance with the FDAs current cGMP
and to complete the analytical and stability work necessary for
a New Drug Application, or NDA, submission for marketing
approval. An NDA will be submitted if the planned Phase III
study is successful, and approval of the NDA is required to
market phenoxodiol. We will need to arrange similar contracts in
the future to secure the supply of triphendiol and NV-143. We
have no direct control over the costs of manufacturing our
product candidates. If the costs of manufacturing increase or if
the cost of the materials used increases, these costs will be
passed on to us making the cost of conducting clinical trials
more expensive. Increases in manufacturing costs could adversely
affect our future profitability if we are unable to pass all of
the increased costs along to our customers.
We may
not be able to secure and maintain suitable research
institutions to conduct our clinical trials.
We rely on suitable research institutions, of which there are
many, to conduct our clinical trials. Our reliance upon research
institutions, including hospitals and cancer clinics, provides
us with less control over the timing and cost of clinical trials
and the ability to recruit patients than if we had conducted the
trials on our own. Further, there is a greater likelihood that
disputes may arise with these research institutions over the
ownership of intellectual property discovered during the
clinical trials. If we are unable to reach agreement with
suitable research institutions on acceptable terms, or if any
resulting agreement is terminated and we are unable to quickly
replace the applicable research institution with another
qualified institution on acceptable terms, the research could be
delayed and we may be unable to complete development, or
commercialize phenoxodiol, triphendiol or NV-143, which will
adversely affect our ability to generate operating revenues.
We
face a risk of product liability claims and may not be able to
obtain adequate insurance.
Our business exposes us to the risk of product liability claims.
This risk is inherent in the manufacturing, testing and
marketing of human therapeutic products. We have product
liability insurance coverage of up to approximately
$17.4 million. Although we believe that this amount of
insurance coverage is appropriate for our business at this time,
it is subject to deductibles and coverage limitations, and the
market for such insurance is becoming more restrictive. We may
not be able to obtain or maintain adequate protection against
potential liabilities. If we are unable to sufficiently insure
against potential product liability claims, we will be exposed
to significant liabilities, which may materially and adversely
affect our business development and commercialization efforts.
6
Our
rights to develop and exploit phenoxodiol and the anti-cancer
compounds triphendiol and NV-143 are subject to the terms and
conditions of agreements we have entered into with Novogen, and
under these agreements our rights may be terminated under
certain circumstances, some of which may be beyond our
control.
We have licensed the intellectual property in the phenoxodiol
technology and the anti-cancer compounds triphendiol and NV-143
from Novogen. Under the terms of the license agreement for
phenoxodiol, all forms of administering phenoxodiol for the
treatment of cancer, excluding topical applications, are
licensed to us through our wholly-owned subsidiary, MEPL. Under
the terms of the license agreement for triphendiol and NV-143,
all forms of administering drugs containing the anti-cancer
compounds triphendiol and NV-143, excluding topical
applications, are licensed to us through MEPL. If we fail to
meet our obligations under our license agreements, the
manufacturing license and supply agreement or the services
agreement with Novogen, any or all of these agreements may be
terminated by Novogen and we could lose our rights to develop
phenoxodiol or anti-cancer drugs containing triphendiol and
NV-143. To date, we have no reason to believe that we will be
unable to satisfy our obligations under these agreements. In
addition, each of these agreements may be terminated immediately
by Novogen in the event that MEPL undergoes a change of control
without the consent of Novogen. Under the terms of the license
agreement for phenoxodiol, the manufacturing license and supply
agreement and the services agreement, a change of
control means a change in control of more than half the
voting rights attaching to the shares of MEPL, a change in
control of more than half of the issued shares of MEPL (not
counting any share which carries no right to participate beyond
a specified amount in the distribution of either profit or
capital) or a change in control of the composition of the board
of directors of MEPL. Under the terms of the license agreement
for triphendiol and NV-143, a change in control
means the acquisition by any person or group of more than half
of the combined voting power of MEPLs then outstanding
securities entitled to vote generally in the election of
directors of MEPL or any merger, consolidation,
recapitalization, exchange or tender offer as a result of which
a person or a group other than the shareholders of MEPL
immediately before the transaction owns after the transaction
more than half of the combined voting power of the then
outstanding securities entitled to vote generally in the
election of directors MEPL. Each of these agreements may also be
terminated if we cease for any reason to be able to lawfully
carry out all the transactions required by each respective
agreement.
Our
license rights are fundamental to our business and therefore a
loss of these rights will likely cause us to cease
operations.
The rights granted to us under the license agreements, the
manufacturing license and supply agreement and the license
option deed with Novogen are fundamental to our business. The
license agreement for phenoxodiol grants us the right to make,
have made, market, distribute, sell, hire or otherwise dispose
of phenoxodiol products in the field of prevention, treatment or
cure of cancer in humans by pharmaceuticals delivered in all
forms except topical applications. The license agreement for
triphendiol and NV-143 grants us the right to make, have made,
market, distribute, sell, hire or otherwise dispose of
anti-cancer drugs containing the compounds triphendiol and
NV-143 in the field of prevention, treatment or cure of cancer
in humans by pharmaceuticals delivered in all forms except
topical applications. Our business purpose is to develop and
commercialize cancer drugs including phenoxodiol and drugs
containing the compounds triphendiol and NV-143, which we would
be unable to pursue without the rights granted to us under the
license agreements. The license option deed grants us an
exclusive first right to accept and exclusive last right to
match any proposed dealing by Novogen with its intellectual
property rights with a third party relating to certain compounds
(other than phenoxodiol) developed by Novogen and its affiliates
which have applications in the field of prevention, treatment or
cure of cancer in humans. The license option deed is important
to our business because it allows us to maintain control over
the sale by Novogen of complementary as well as potentially
competitive intellectual property rights to third party
competitors. Any loss of the rights under any of these
agreements will likely cause us to cease operations.
The
success of our product candidates is largely dependent on
Novogens ability to obtain and maintain patent protection
and preserve trade secrets, which cannot be
guaranteed.
Patent protection and trade secret protection are important to
our business and our future will depend, in part on our ability
and the ability of Novogen to maintain trade secret protection,
obtain patents and operate without
7
infringing the proprietary rights of others both in the United
States and abroad. Litigation or other legal proceedings may be
necessary to defend against claims of infringement, to enforce
our patents, or to protect our trade secrets or the trade
secrets of Novogen. Such litigation could result in substantial
costs and diversion of our managements attention. Novogen
has not been involved in any opposition, re-examination, trade
secret dispute, infringement litigation or any other litigation
or legal proceedings pertaining to the licensed patent rights.
The patent positions of pharmaceutical and biotechnology
companies can be highly uncertain and involve complex legal and
factual questions. Novogen has applied for patents in a number
of countries with respect to the use of phenoxodiol for the
treatment, prevention or cure of cancer and methods of
production of phenoxodiol. We have licensed both issued patents
and pending patent applications from Novogen in relation to
these technologies. Novogen has recently been issued a United
States patent for pharmaceutical compositions comprising
phenoxodiol. Novogen has issued patents in the United States,
the United Kingdom, Australia, China, Hong Kong, New Zealand,
Singapore, Mexico and the Czech Republic related to phenoxodiol
for the treatment of a variety of cancers and has issued patents
in the United States, Australia, New Zealand, Singapore and
Sweden covering the use of phenoxodiol to prevent or treat skin
cancer resulting from ultraviolet damage. Issued Novogen patents
in the United States, Europe, Australia, New Zealand, Singapore,
Mexico and Sweden cover the use of phenoxodiol to treat or
prevent UV-induced immunosuppression. In addition, Novogen has
issued patents in Australia, New Zealand, Singapore, South
Africa and Turkey relating to methods of production of
phenoxodiol. For each of the patent families discussed above,
there remain pending patent applications in various other
jurisdictions.
Novogens patent applications may not proceed to grant or
may be amended to reduce the scope of protection of any patent
granted. The applications and patents may also be opposed or
challenged by third parties. Our commercial success will depend,
in part, on the ability of Novogen and our ability to obtain and
maintain effective patent protection for the technologies
underlying phenoxodiol and other compounds, and to successfully
defend patent rights in those technologies against third-party
challenges. As patent applications in the United States are
maintained in secrecy until published or issued and as
publication of discoveries in the scientific or patent
literature often lag behind the actual discoveries, we cannot be
certain that Novogen was the first to make the inventions
covered by its pending patent applications or issued patents or
that it was the first to file patent applications for such
inventions. Additionally, the breadth of claims allowed in
biotechnology and pharmaceutical patents or their enforceability
cannot be predicted. We cannot be sure that, should any patents
issue, we will be provided with adequate protection against
potentially competitive products. Furthermore, we cannot be sure
that should patents issue, they will be of commercial value to
us, or that private parties, including competitors, will not
successfully challenge our patents or circumvent our patent
position in the United States or abroad.
Claims
by other companies that we infringe their proprietary technology
may result in liability for damages or stop our development and
commercialization efforts.
The pharmaceutical industry is highly competitive and patents
have been applied for by, and issued to, other parties relating
to products competitive with phenoxodiol. Therefore, phenoxodiol
and any other drug candidates may give rise to claims that they
infringe the patents or proprietary rights of other parties
existing now and in the future. Furthermore, to the extent that
we or Novogen or our respective consultants or research
collaborators use intellectual property owned by others in work
performed for us or Novogen, disputes may also arise as to the
rights in such intellectual property or in resulting know-how
and inventions. An adverse claim could subject us to significant
liabilities to such other parties
and/or
require disputed rights to be licensed from such other parties.
We have currently contracted formulation development and
manufacturing process development work for phenoxodiol. This
work is being conducted to ensure that there is a robust
production process which meets the expected commercial
quantities of phenoxodiol and that dose formulations are
manufactured on a cost effective basis.
This process has identified a number of excipients, or additives
to improve drug delivery, which may be used in the formulations
of phenoxodiol. Excipients, among other things, perform the
function of a carrier of the active drug ingredient. Some of
these identified excipients or carriers may be included in third
party patents in some countries. We intend to seek a license if
we decide to use a patented excipient in the marketed product or
we may choose one of those excipients that do not have a license
requirement.
8
We cannot be sure that any license required under any such
patents or proprietary rights would be made available on terms
acceptable to us, if at all. If we do not obtain such licenses,
we may encounter delays in product market introductions, or may
find that the development, manufacture or sale of products
requiring such licenses may be precluded. We have not conducted
any searches or made any independent investigations of the
existence of any patents or proprietary rights of other parties.
We may
be subject to substantial costs stemming from our defense
against third-party intellectual property infringement
claims.
Third parties may assert that we or Novogen are using their
proprietary information without authorization. Third parties may
also have or obtain patents and may claim that technologies
licensed to or used by us infringe their patents. If we are
required to defend patent infringement actions brought by third
parties, or if we sue to protect our own patent rights, we may
be required to pay substantial litigation costs and managerial
attention may be diverted from business operations even if the
outcome is not adverse to us. In addition, any legal action that
seeks damages or an injunction to stop us from carrying on our
commercial activities relating to the affected technologies
could subject us to monetary liability and require us or Novogen
or any third party licensors to obtain a license to continue to
use the affected technologies. We cannot predict whether we or
Novogen would prevail in any of these types of actions or that
any required license would be made available on commercially
acceptable terms or at all.
In the
event that Novogen does not comply with its obligations under a
grant from the Australian Government under which phenoxodiol
was, in part, developed, our rights to use the intellectual
property relating to phenoxodiol and developed by Novogen may
revert back to the Australian Government.
Novogen developed phenoxodiol in part by using funds from the
Australian Government under what is known as the START Program.
Under the START Program, Novogen must meet certain project
development and commercialization obligations. Novogen has met
the project development obligations and has received final
payment thereon. Novogen believes it is currently in compliance
with its commercialization schedule. Although Novogen believes
that it has complied with its obligations under the START
Program, if the Australian Government disagrees or if Novogen
undergoes a change of control without the prior consent of the
Australian Government, the Australian Government has a right to
demand that intellectual property created during the course of
the project funded by the grant be vested back in the Australian
Government or demand repayment of the funds paid to Novogen
under the program. The Australian Government may then license
the intellectual property rights related to phenoxodiol to other
parties and may demand other intellectual property rights from
Novogen. Any such reclamation by the Australian Government could
preclude our use of Novogens intellectual property in the
development and commercialization of phenoxodiol and we may have
to compete with other companies to whom the Australian
Government may license the intellectual property.
The
enforcement of civil liabilities against our officers and
directors may be difficult.
Most of our officers and directors are residents of
jurisdictions outside the United States. As a result it may be
difficult for you to effect service of process within the United
States upon all our officers and directors or to enforce
judgments obtained against all our officers and directors or us
in United States courts.
Our
results are affected by fluctuations in currency exchange
rates.
Much of our expenditures and potential revenue will be spent or
derived outside of the United States. As a result, fluctuations
between the United States dollar and the currencies of the
countries in which we operate may increase our costs or reduce
our potential revenue. At present, we do not engage in hedging
transactions to protect against uncertainty in future exchange
rates between particular foreign currencies and the
U.S. dollar.
We are
authorized to issue a class of blank check preferred stock,
which could adversely affect the holders of our common
stock.
Our restated certificate of incorporation allows us to issue a
class of blank check preferred stock with rights potentially
senior to those of our common stock without any further vote or
action by the holders of our common
9
stock. The issuance of preferred stock could decrease the amount
of earnings and assets available for distribution to the holders
of our common stock or could adversely affect the rights and
powers including voting rights, of such holders. In certain
circumstances such issuance could have the effect of decreasing
the market price of our shares, or making a change in control of
us more difficult.
Risks
Related to Our Relationship with Novogen
As our
majority stockholder, Novogen has the ability to determine the
outcome of all matters submitted to our stockholders for
approval and Novogens interests may conflict with ours or
our other stockholders interests.
Novogen beneficially owns approximately 71.9% of our outstanding
shares of common stock. As a result, Novogen will have the
ability to effectively determine the outcome of all matters
submitted to our stockholders for approval, including the
election and removal of directors and any merger, consolidation
or sale of all or substantially all of our assets.
Novogen will have the ability to effectively control our
management and affairs. Novogens interests may not always
be the same as that of our other stockholders. In addition this
concentration of ownership may harm the market price of our
securities by:
|
|
|
|
|
delaying, deferring or preventing a change in control;
|
|
|
|
impeding a merger, consolidation, takeover or other business
combination involving us;
|
|
|
|
discouraging a potential acquirer from making a tender, offer or
otherwise attempting to obtain control of us; or
|
|
|
|
selling us to a third party.
|
Three
of our directors and our secretary and chief financial officer
are officers and/or directors of Novogen Limited and other
Novogen subsidiaries, which may create a conflict of interest as
well as prevent them from devoting their full attention to
us.
Three of our board members currently serve as board members of
Novogen Limited. Simultaneous service as a Novogen Limited
director or officer could create, or appear to create, a
conflict of interest when such directors are presented with
decisions that could have different implications for us and
Novogen Limited.
Mr. Philip Johnston is the chairman of Novogen Limited,
Mr. Christopher Naughton is the managing director of
Novogen Limited and Professor Paul John Nestel is a director of
Novogen Limited. Mr. David Seaton is the chief financial
officer of Novogen Limited. The responsibilities of
Messrs. Johnston, Naughton and Seaton and Professor Nestel
to Novogen Limited could prevent them from devoting their full
attention to us, which could be harmful to the development of
our business.
We
depend on a number of key personnel whose services are provided
by Novogen under our services agreement. If we are not able to
procure these services in the future, the strategic direction of
the clinical development program would be disrupted, causing a
delay in our commercialization program.
We currently rely on Professor Alan Husband, Novogen Research
Director, and Mr. Christopher Naughton, our President and
Chief Executive Officer, to provide the strategic direction for
the clinical development of phenoxodiol. If we are unable to
secure the ongoing services of these key personnel, the
commercialization program for phenoxodiol will be disrupted and
will cause delays in obtaining marketing approval. Novogen has
entered into employment agreements with Professor Husband and
Mr. Naughton.
Novogen
can compete with us.
We have no contract, arrangement or understanding with Novogen
to preclude it from developing a product which may be
competitive with phenoxodiol, triphendiol or NV-143 or to use
these compounds for any uses other than anti-cancer
applications. Novogen has reserved the intellectual property
rights and know-how rights relating to
10
topical applications of these compounds even in the field of
cancer. There can be no assurance that Novogen or its
subsidiaries will not pursue alternative technologies or product
candidates as a means of developing treatments for the
conditions targeted by phenoxodiol or any other product
candidate which we seek to exploit.
We are
dependent on Novogen for our personnel.
We have no employees. We rely on Novogen to provide or procure
the provision of staff and other financial and administrative
services under our services agreement with Novogen. We believe
Novogen has fully complied with the terms of our services
agreement. To successfully develop our drug candidates, we will
require ongoing access to the personnel who have, to date, been
responsible for the development of our drug candidates. The
services agreement does not specify a minimum amount of time
that Novogen employees must devote to our operations. If we are
unable to secure or if we lose the services of these personnel,
the ability to develop our drug candidates could be materially
impaired. Moreover, if our business experiences substantial and
rapid growth, we may not be able to secure the services and
resources we require from Novogen or from other persons to
support that growth.
In the
event that Novogen undergoes a change in control while remaining
our controlling stockholder, we will become subject to the
control and influence of Novogens new controlling
stockholder who may have views regarding the development of our
business that differ from the development strategies we are
currently pursuing.
In the event that Novogen undergoes a change in control while
remaining our controlling stockholder, we will become subject to
the control and influence of Novogens new controlling
stockholder who will have the ability to indirectly determine
the outcome of all matters submitted to our stockholders for
approval through its control of Novogen. This entity may have
views regarding the development of our business that differ from
the development strategies we are currently pursuing. Such
controlling stockholder may cause Novogen to use its influence
and voting power to change the direction in which we are
developing our business. Such changes may include, but are not
limited to, a decreased focus on the development of any of our
current drug candidates and an increased focus on the
development of alternative drug candidates, which may or may not
be targeted to treat cancers. Additionally, this entity make
seek to reneogiate the terms of our existing license agreements,
manufacturing and supply agreement and services agreement with
Novogen.
Risks
Related to Our Common Stock
The
trading price of the shares of our common stock could be highly
volatile and could decline in value and we may incur significant
costs from class action litigation.
The trading price of our common stock could be highly volatile
in response to various factors, many of which are beyond our
control, including:
|
|
|
|
|
developments concerning phenoxodiol and our other drug
candidates triphendiol and NV-143;
|
|
|
|
announcements of technological innovations by us or our
competitors;
|
|
|
|
new products introduced or announced by us or our competitors;
|
|
|
|
changes in financial estimates by securities analysts;
|
|
|
|
actual or anticipated variations in operating results;
|
|
|
|
expiration or termination of licenses, research contracts or
other collaboration agreements;
|
|
|
|
conditions or trends in the regulatory climate and the
biotechnology, pharmaceutical and genomics industries;
|
|
|
|
changes in the market valuations of similar companies;
|
|
|
|
the liquidity of any market for our securities; and
|
|
|
|
additional sales by us or Novogen of shares of our common stock.
|
11
In addition, equity markets in general, and the market for
biotechnology and life sciences companies in particular, have
experienced substantial price and volume fluctuations that have
often been unrelated or disproportionate to the operating
performance of companies traded in those markets. In addition,
changes in economic conditions in the United States, Europe or
globally, could impact upon our ability to grow profitably.
Adverse economic changes are outside our control and may result
in material adverse impacts on our business or our results of
operations. These broad market and industry factors may
materially affect the market price of our shares of common
stock, regardless of our development and operating performance.
In the past, following periods of volatility in the market price
of a companys securities, securities
class-action
litigation has often been instituted against that company. Such
litigation, if instituted against us, could cause us to incur
substantial costs and divert managements attention and
resources.
Future
sales of our common stock may depress the market price of our
common stock and cause stockholders to experience
dilution.
The market price of our common stock could decline as a result
of sales of substantial amounts of our common stock in the
public market, or the perception that these sales could occur.
We
will have broad discretion over the use of the net proceeds to
us from any exercise of outstanding warrants.
We will have broad discretion to use the net proceeds to us upon
any exercise of outstanding warrants, and you will be relying on
the judgment of our board of directors and management regarding
the application of these proceeds. Although we expect to use a
substantial portion of the net proceeds from any exercise of the
warrants for general corporate purposes, including potential
payments to Novogen under the terms of the license agreements,
potential licensing of other cancer compounds developed by
Novogen under the license option deed and potential expansion of
the clinical trial program for phenoxodiol to include other
forms of cancer, we have not allocated these net proceeds for
specific purposes.
Risks
Related to Completed Private Placements
If we
fail to maintain registration of the common stock issued or
issuable pursuant to the exercise of warrants we issued in
connection with the securities subscription agreements we
entered into with certain stockholders effective July 11,
2006 and August 1, 2007, we may be obligated to pay such
stockholders liquidated damages.
In connection with the securities subscription agreement we
entered into with certain stockholders effective July 11,
2006, we also entered into a registration rights agreement
pursuant to which we are obligated to file a resale registration
statement with the SEC covering the shares of common stock
issued in connection with the securities subscription agreement,
in addition to the shares of common stock underlying the
warrants issued in connection with the securities subscription
agreement. We filed the registration statement on August 9,
2006. The registration statement was declared effective on
September 5, 2006.
In connection with the securities subscription agreement we
entered into with certain stockholders effective August 1,
2007, we also entered into a registration rights agreement
pursuant to which we are obligated to file a resale registration
statement with the SEC by the fifth calendar day following the
filing of the our Annual Report on
Form 10-K
for the fiscal year ended June 30, 2007, covering the
shares of common stock issued in connection with the securities
subscription agreement, in addition to the shares of common
stock underlying the warrants issued in connection with the
securities subscription agreement. We filed the registration
statement on October 2, 2007. The registration statement
was declared effective on October 19, 2007.
In the event that either registration statement ceases to be
effective or usable at any time while shares of common stock
covered by it remain unsold or may only be sold subject to
certain volume limitations, and the stockholders party to the
registration rights agreements are not permitted to utilize the
prospectus in connection with the registration statement to
resell shares of common stock covered by the registration
statement, we will be obligated to pay stockholders who
purchased shares of common stock in the private placements
liquidated damages equal to 1% of the aggregate purchase price
paid by each stockholder pursuant to the securities subscription
12
agreements for any shares of common stock or shares of common
stock issuable upon exercise of warrants then held by each
investor per month (pro rated for any period less than a month)
until the registration statement is effective or the investors
are permitted to utilize the prospectus in connection with the
registration statement to resell shares of common stock covered
by the registration statement.
Liquidated damages paid to each investor in the private
placements may not exceed 10% of the purchase price paid by such
investor for shares of common stock or shares of common stock
issuable upon exercise of warrants purchased under the
securities subscription agreements. If we become obligated to
pay liquidated damages, we would deplete our limited working
capital and potentially need to raise additional funds.
Additionally, the payment of liquated damages would negatively
impact our ability to complete future private placements.
CAUTIONARY
STATEMENT ABOUT FORWARD-LOOKING STATEMENTS
This prospectus and the documents incorporated by reference
herein contain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended and
Section 21E of the Securities Exchange Act of 1934, as
amended. All statements other than statements of historical
facts contained in this prospectus and the documents
incorporated by reference herein, including statements regarding
the future financial position, business strategy and plans and
objectives of management for future operations, are
forward-looking statements. The words believe,
may, will, estimate,
continue, anticipate,
intend, should, plan,
expect, and similar expressions, as they relate to
us, are intended to identify forward-looking statements. We have
based these forward-looking statements largely on current
expectations and projections about future events and financial
trends that we believe may affect financial condition, results
of operations, business strategy and financial needs. These
forward-looking statements are subject to a number of risks,
uncertainties and assumptions, including, without limitation,
those described in Risk Factors and elsewhere in
this prospectus and the documents incorporated by reference
herein, including, among other things:
|
|
|
|
|
our inability to obtain required additional financing or
financing available to us on acceptable terms;
|
|
|
|
costs and delays in the development
and/or
receipt of FDA or other required governmental approvals, or the
failure to obtain such approvals, for our product candidates;
|
|
|
|
uncertainties in clinical trial results;
|
|
|
|
our failure to successfully commercialize our product candidates;
|
|
|
|
our limited operating history;
|
|
|
|
our inability to maintain or enter into, and the risks resulting
from our dependence upon, collaboration or contractual
arrangements necessary for the development, manufacture,
commercialization, marketing, sales and distribution of any
products;
|
|
|
|
our inability to control the costs of manufacturing our products;
|
|
|
|
competition and competitive factors;
|
|
|
|
our inability to protect our patents or proprietary rights and
obtain necessary rights to third party patents and intellectual
property to operate our business;
|
|
|
|
our inability to operate our business without infringing the
patents and proprietary rights of others;
|
|
|
|
costs stemming from our defense against third party intellectual
property infringement claims;
|
|
|
|
continued cooperation and support of Novogen Limited, our parent
company;
|
|
|
|
difficulties in enforcement of civil liabilities against our
officers and directors who are residents of jurisdictions
outside the United States;
|
|
|
|
general economic conditions;
|
|
|
|
the failure of any products to gain market acceptance;
|
13
|
|
|
|
|
technological changes;
|
|
|
|
government regulation generally and the receipt of the
regulatory approvals;
|
|
|
|
changes in industry practice; and
|
|
|
|
one-time events.
|
These risks are not exhaustive. Other sections of this
prospectus and the documents incorporated by reference herein
include additional factors which could adversely impact our
business and financial performance. Moreover, we operate in a
very competitive and rapidly changing environment. New risk
factors emerge from time to time and it is not possible for us
to predict all risk factors, nor can we assess the impact of all
factors on our business or the extent to which any factor, or
combination of factors, may cause actual results to differ
materially from those contained in any forward-looking
statements.
You should not rely upon forward looking statements as
predictions of future events. We cannot assure you that the
events and circumstances reflected in the forward looking
statements will be achieved or occur. Although we believe that
the expectations reflected in the forward looking statements are
reasonable, we cannot guarantee future results, levels of
activity, performance or achievements.
SECURITIES
OFFERED BY THIS PROSPECTUS
Using this prospectus, we may offer from time to time, in one or
more series, together or separately, at prices and terms to be
determined at the time of offering:
|
|
|
|
|
shares of common stock, $0.00000002 par value;
|
|
|
|
shares of preferred stock, $0.01 par value; and
|
|
|
|
warrants to purchase shares of common stock or preferred stock.
|
The shares of preferred stock may be convertible into or
exchangeable for shares of our common stock or preferred stock
issued by us.
See Description of Securities for a description of
the terms of the common stock, preferred stock and warrants.
USE OF
PROCEEDS
Although we expect to use a substantial portion of the net
proceeds from the sale of securities under this prospectus for
general corporate purposes, including potential payments to
Novogen under the terms of the license agreements, potential
licensing of other cancer compounds developed by Novogen under
the license option deed and potential expansion of the clinical
trial programs for phenoxodiol and triphendiol, we have not
allocated these net proceeds for specific purposes. If, as of
the date of any prospectus supplement, we have identified any
additional use for the net proceeds, we will describe them in
the prospectus supplement. The amount of securities offered from
time to time pursuant to this prospectus and any prospectus
supplement, and the precise amount of the net proceeds we will
receive from the sale of such securities, as well as the timing
of receipt of those proceeds, will depend upon our funding
requirements. If we elect at the time of an issuance of
securities to make different or more specific uses of the
proceeds than as set forth herein, we will describe those uses
in the applicable prospectus supplement.
RATIOS OF
EARNINGS TO COMBINED FIXED CHARGES AND PREFERRED STOCK
DIVIDENDS
We did not have any earnings or fixed charges for the six months
ended December 31, 2007 or the years ended June 30,
2007, 2006, 2005, 2004 and 2003. We also did not have any shares
of preferred stock outstanding during these periods.
14
PLAN OF
DISTRIBUTION
We may sell the securities included in this prospectus
(i) through agents, (ii) through underwriters,
(iii) through dealers or (iv) through a combination of
any such methods of sale.
The distribution of the securities may be effected from time to
time in one or more transactions:
|
|
|
|
|
at a fixed price or at final prices, which may be changed;
|
|
|
|
at market prices prevailing at the time of sale;
|
|
|
|
at prices related to such prevailing market prices; or
|
|
|
|
at negotiated prices.
|
Offers to purchase securities may be solicited directly by us,
or by agents designated by us, from time to time. Any such
agent, which may be deemed to be an underwriter as that term is
defined in the Securities Act of 1933, as amended, involved in
the offer or sale of the securities in respect of which this
prospectus is delivered will be named, and any commissions
payable by us to such agent will be set forth, in the applicable
prospectus supplement.
If an underwriter is, or underwriters are, utilized in the offer
and sale of securities in respect of which this prospectus and
the accompanying prospectus supplement are delivered, we will
execute an underwriting agreement with such underwriter(s) for
the sale to it or them and the name(s) of the underwriter(s) and
the terms of the transaction, including any underwriting
discounts and other items constituting compensation of the
underwriters and dealers, if any, will be set forth in such
prospectus supplement, which will be used by the underwriter(s)
to make resales of the securities in respect of which this
prospectus and such prospectus supplement are delivered to the
public. The securities will be acquired by the underwriters for
their own accounts and may be resold from time to time in one or
more transactions, including negotiated transactions, at a fixed
public offering price or at varying prices determined at the
time of sale. Any initial public offering price and any
discounts or concessions allowed or reallowed or paid to dealers
may be changed from time to time.
If a dealer is utilized in the sale of the securities in respect
of which this prospectus is delivered, we will sell such
securities to the dealer, as principal. The dealer may then
resell such securities to the public at varying prices to be
determined by such dealer at the time of resale. The name of the
dealer and the terms of the transaction will be identified in
the applicable prospectus supplement.
If an agent is used in an offering of securities being offered
by this prospectus, the agent will be named, and the terms of
the agency will be described, in the applicable prospectus
supplement relating to the offering. Unless otherwise indicated
in the prospectus supplement, an agent will act on a best
efforts basis for the period of its appointment.
If indicated in the applicable prospectus supplement, we will
authorize underwriters or their other agents to solicit offers
by certain institutional investors to purchase securities from
us pursuant to contracts providing for payment and delivery at a
future date. Institutional investors with which these contracts
may be made include commercial and savings banks, insurance
companies, pension funds, investment companies, educational and
charitable institutions and others. In all cases, these
purchasers must be approved by us. The obligations of any
purchaser under any of these contracts will not be subject to
any conditions except that (a) the purchase of the
securities must not at the time of delivery be prohibited under
the laws of any jurisdiction to which that purchaser is subject,
and (b) if the securities are also being sold to
underwriters, we must have sold to these underwriters the
securities not subject to delayed delivery. Underwriters and
other agents will not have any responsibility in respect of the
validity or performance of these contracts.
Certain of the underwriters, dealers or agents utilized by us in
any offering hereby may be customers of, including borrowers
from, engage in transactions with, and perform services for us
or one or more of our affiliates in the ordinary course of
business. Underwriters, dealers, agents and other persons may be
entitled, under agreements which may be entered into with us, to
indemnification against certain civil liabilities, including
liabilities under the Securities Act of 1933, as amended.
15
Until the distribution of the securities is completed, rules of
the SEC may limit the ability of the underwriters and certain
selling group members, if any, to bid for and purchase the
securities. As an exception to these rules, the representatives
of the underwriters, if any, are permitted to engage in certain
transactions that stabilize the price of the securities. Such
transactions may consist of bids or purchases for the purpose of
pegging, fixing or maintaining the price of the securities.
If underwriters create a short position in the securities in
connection with the offering thereof (in other words, if they
sell more securities than are set forth on the cover page of the
applicable prospectus supplement), the representatives of such
underwriters may reduce that short position by purchasing
securities in the open market. Any such representatives also may
elect to reduce any short position by exercising all or part of
any over-allotment option described in the applicable prospectus
supplement.
Any such representatives also may impose a penalty bid on
certain underwriters and selling group members. This means that
if the representatives purchase securities in the open market to
reduce the underwriters short position or to stabilize the
price of the securities, they may reclaim the amount of the
selling concession from the underwriters and selling group
members who sold those shares as part of the offering thereof.
In general, purchases of a security for the purpose of
stabilization or to reduce a syndicate short position could
cause the price of the security to be higher than it might
otherwise be in the absence of such purchases. The imposition of
a penalty bid might have an effect on the price of a security to
the extent that it was to discourage resales of the security by
purchasers in the offering.
Neither we nor any of the underwriters, if any, makes any
representation or prediction as to the direction or magnitude of
any effect that the transactions described above may have on the
price of the securities. In addition, neither we nor any of the
underwriters, if any, makes any representation that the
representatives of the underwriters, if any, will engage in such
transactions or that such transactions, once commenced, will not
be discontinued without notice.
The anticipated date of delivery of the securities offered by
this prospectus will be described in the applicable prospectus
supplement relating to the offering. The securities offered by
this prospectus may or may not be listed on a national
securities exchange or a foreign securities exchange. We cannot
give any assurances that there will be a market for any of the
securities offered by this prospectus and any prospectus
supplement.
We will bear costs relating to all of the securities being
registered under this prospectus, other than underwriters
discounts and commissions.
DESCRIPTION
OF SECURITIES
Common
Stock
For a description of our common stock, please see our
Registration Statement on
Form 8-A
filed with the SEC on November 26, 2003 and any further
amendment or report filed thereafter for the purpose of updating
such description.
Preferred
Stock
The material terms of any series of preferred stock that we
offer through a prospectus supplement will be described in that
prospectus supplement. Our board of directors is authorized to
provide for the issuance of blank check preferred stock in one
or more series with designations as may be stated in the
resolution or resolutions providing for the issue of such
preferred shares. At the time that any series of our preferred
stock is authorized, our board of directors will fix the
dividend rights, any conversion rights, any voting rights,
redemption provisions, liquidation preferences and any other
rights, preferences, privileges and restrictions of that series,
as well as the number of shares constituting that series and
their designation. Our board of directors could, without
stockholder approval, cause us to issue preferred stock which
has voting, conversion and other rights that could adversely
affect the holders of our common stock or make it more difficult
to effect a change in control. Our preferred stock could be used
to dilute the share ownership of persons seeking to obtain
control of us and thereby hinder a possible takeover
16
attempt which, if our stockholders were offered a premium over
the market value of their shares, might be viewed as being
beneficial to our stockholders. In addition, our preferred stock
could be issued with voting, conversion and other rights and
preferences which would adversely affect the voting power and
other rights of holders of our common stock.
Warrants
We may issue warrants to purchase our common stock or preferred
stock. Warrants may be issued independently or together with any
other securities and may be attached to, or separate from, such
securities. Each series of warrants will be issued under a
separate warrant agreement to be entered into between us and a
warrant agent. The terms of any warrants to be issued and a
description of the material provisions of the applicable warrant
agreement will be set forth in the applicable prospectus
supplement.
The applicable prospectus supplement will describe the following
terms of any warrants in respect of which this prospectus is
being delivered:
|
|
|
|
|
the title of such warrants;
|
|
|
|
the aggregate number of such warrants;
|
|
|
|
the price or prices at which such warrants will be issued;
|
|
|
|
the currency or currencies, in which the price of such warrants
will be payable;
|
|
|
|
the securities purchasable upon exercise of such warrants;
|
|
|
|
the price at which and the currency or currencies, in which the
securities or other rights purchasable upon exercise of such
warrants may be purchased;
|
|
|
|
the date on which the right to exercise such warrants shall
commence and the date on which such right shall expire;
|
|
|
|
if applicable, the minimum or maximum amount of such warrants
which may be exercised at any one time;
|
|
|
|
if applicable, the designation and terms of the securities with
which such warrants are issued and the number of such warrants
issued with each such security;
|
|
|
|
if applicable, the date on and after which such warrants and the
related securities will be separately transferable;
|
|
|
|
information with respect to book-entry procedures, if any;
|
|
|
|
if applicable, a discussion of any material United States
Federal income tax considerations; and
|
|
|
|
any other terms of such warrants, including terms, procedures
and limitations relating to the exchange and exercise of such
warrants.
|
LEGAL
MATTERS
The validity of the securities described herein has been passed
upon for us by Morgan, Lewis & Bockius LLP.
EXPERTS
The consolidated financial statements of Marshall Edwards, Inc.
(a development stage company) as of June 30, 2007 and
June 30, 2006, and the related statements of operations,
stockholders equity and cash flows for each of the years
in the three-year period ended June 30, 2007 and for the
period from December 1, 2000 (inception) through
June 30, 2007, appearing in Marshall Edwards, Inc.s
Annual Report
(Form 10-K)
for the year ended June 30, 2007, are incorporated herein
by reference. Such financial statements have been audited by BDO
Kendalls (NSW), an independent registered public accounting
firm, to the extent and for the periods set forth in their
report incorporated
17
herein by reference, and are incorporated herein in reliance
upon such report given upon the authority of said firm as
experts in auditing and accounting.
INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE
The SEC allows us to incorporate by reference into
this prospectus the information we have filed with the SEC,
which means that we can disclose important information to you by
referring you to those documents. Any information that we file
subsequently with the SEC will automatically update this
prospectus. We incorporate by reference into this prospectus the
information contained in the documents listed below, which are
considered to be a part of this prospectus:
|
|
|
|
|
Our Annual Report on
Form 10-K
for the fiscal year ended June 30, 2007 filed on
September 27, 2007;
|
|
|
|
Our Current Report on
Form 8-K
filed on July 30, 2007;
|
|
|
|
Our Current Report on
Form 8-K
filed on August 6, 2007;
|
|
|
|
Our Current Report on
Form 8-K
filed on August 21, 2007;
|
|
|
|
Our Current Report on
Form 8-K/A
filed on September 27, 2007;
|
|
|
|
Our Quarterly Report for the fiscal quarter ended
September 30, 2007 filed on November 7, 2007;
|
|
|
|
Our Quarterly Report for the fiscal quarter ended
December 31, 2007, filed on February 8, 2008; and
|
|
|
|
The description of our common stock contained in the
Registration Statement on Form
8-A filed on
November 26, 2003 and any further amendment or report filed
thereafter for the purpose of updating such description.
|
We also incorporate by reference all documents we subsequently
file pursuant to Section 13(a), 13(c), 14 or 15(d) of the
Securities Exchange Act of 1934, as amended after the initial
filing date of the registration statement of which this
prospectus is a part and prior to the termination of the
offering. The most recent information that we file with the SEC
automatically updates and supersedes older information. The
information contained in any such filing will be deemed to be a
part of this prospectus, commencing on the date on which the
document is filed.
If you request, either orally or in writing, we will provide you
with a copy of any or all documents which are incorporated by
reference. We will provide such documents to you free of charge,
but will not include any exhibits, unless those exhibits are
incorporated by reference into the document. You should address
written requests for documents to David R. Seaton, Chief
Financial Officer and Secretary, Marshall Edwards, Inc. 140
Wicks Road, North Ryde NSW 2113 Australia.
WHERE YOU
CAN FIND MORE INFORMATION
We file annual, quarterly and current reports, proxy statements
and other information with the SEC. Our SEC filings are
available to the public over the Internet at the SECs
website at
http://www.sec.gov.
The SECs website contains reports, proxy statements and
other information regarding issuers, such as Marshall Edwards,
that file electronically with the SEC. You may also read and
copy any document we file with the SEC at the SECs Public
Reference Room at 100 F Street, N.E.,
Washington, D.C. 20549. You may also obtain copies of the
documents at prescribed rates by writing to the SECs
Public Reference Section at 100 F Street, N.E.,
Washington, D.C. 20549. Please call the SEC at
1-800-SEC-0330
for further information on the operation of its Public Reference
Room.
18
PART II
INFORMATION
NOT REQUIRED IN PROSPECTUS
|
|
Item 14.
|
Other
Expenses of Issuance and Distribution
|
The following table lists the costs and expenses payable by the
registrant in connection with the sale of the common stock
covered by this prospectus other than any sales commissions or
discounts, which expenses will be paid by the selling
stockholders. All amounts shown are estimates except the SEC
registration fee.
|
|
|
|
|
SEC registration fee
|
|
$
|
2,947.50
|
|
Printing and engraving fees
|
|
|
50,000.00
|
|
Legal fees
|
|
|
100,000.00
|
|
Accounting fees
|
|
|
25,000.00
|
|
Miscellaneous
|
|
|
20,000.00
|
|
|
|
|
|
|
Total
|
|
$
|
197,947.50
|
|
|
|
|
|
|
|
|
Item 15.
|
Indemnification
of Directors and Officers
|
Our Restated Certificate of Incorporation provides that we will
indemnify our directors and officers to the full extent
permitted by the Delaware General Corporation Law, or DGCL.
Section 145 of the DGCL provides that the extent to which a
corporation may indemnify its directors and officers depends on
the nature of the action giving rise to the indemnification
right. In actions not on behalf of the corporation, directors
and officers may be indemnified for acts taken in good faith and
in a manner reasonably believed to be in or not opposed to the
best interests of the corporation. In actions on behalf of the
corporation, directors and officers may be indemnified for acts
taken in good faith and in a manner reasonably believed to be in
or not opposed to the best interests of the corporation, except
for acts as to which the director or officer is adjudged liable
to the corporation, unless the relevant court determines that
indemnification is appropriate despite such liability.
Section 145 of the DGCL also permits a corporation to
(i) reimburse present or former directors or officers for
their defense expenses to the extent they are successful on the
merits or otherwise and (ii) advance defense expenses upon
receipt of an undertaking to repay the corporation if it is
determined that payment of such expenses is unwarranted.
To supplement the general indemnification right contained in our
Restated Certificate of Incorporation, our Amended and Restated
By-Laws provide for the specific indemnification rights
permitted by Section 145 (as described above). Our Amended
and Restated By-Laws also permit us to purchase
Directors & Officers insurance, but no director or
officer has a right to require this.
In addition to the indemnification rights described above, our
Certificate of Incorporation eliminates any monetary liability
of directors to us or our stockholders for breaches of fiduciary
duty except for (i) breaches of the duty of loyalty,
(ii) acts or omissions in bad faith, (iii) improper
dividends or share redemptions and (iv) transactions from
which the director derives an improper personal benefit.
See Exhibit Index following signature page.
The undersigned registrant hereby undertakes:
(1) To file, during any period in which offers or sales are
being made, a post-effective amendment to this registration
statement:
(i) To include any prospectus required by
Section 10(a)(3) of the Securities Act of 1933;
(ii) To reflect in the prospectus any facts or events
arising after the effective date of the registration statement
(or the most recent post-effective amendment thereof) which,
individually or in the aggregate,
II-1
represent a fundamental change in the information set forth in
the registration statement. Notwithstanding the foregoing, any
increase or decrease in volume of securities offered (if the
total dollar value of securities offered would not exceed that
which was registered) and any deviation from the low or high end
of the estimated maximum offering range may be reflected in the
form of prospectus filed with the Commission pursuant to
Rule 424(b) if, in the aggregate, the changes in volume and
price represent no more than a 20 percent change in the
maximum aggregate offering price set forth in the
Calculation of Registration Fee table in the
effective registration statement;
(iii) To include any material information with respect to
the plan of distribution not previously disclosed in the
registration statement or any material change to such
information in the registration statement. Provided, however,
that paragraphs (1)(i), (1)(ii) and (1)(iii) above do not apply
if the registration statement is on
Form S-3
or
Form F-3
and the information required to be included in a post-effective
amendment by those paragraphs is contained in reports filed with
or furnished to the Commission by the registrant pursuant to
section 13 or 15(d) of the Securities Exchange Act of 1934
that are incorporated by reference in the registration
statement, or is contained in a form of prospectus filed
pursuant to Rule 424(b)) that is part of the registration
statement.
(2) That, for the purpose of determining any liability
under the Securities Act of 1933, each such post-effective
amendment shall deemed to be a new registration statement
relating to the securities offered therein, and the offering of
such securities at that time shall be deemed to be the initial
bona fide offering thereof.
(3) To remove from registration by means of a
post-effective amendment any of the securities being registered
which remain unsold at the termination of the offering.
(4) That, for the purpose of determining liability under
the Securities Act of 1933 to any purchaser:
(i) If the registrant is relying on Rule 430B:
(a) Each prospectus filed by the registrant pursuant to
Rule 424(b)(3) shall be deemed to be part of the
registration statement as of the date the filed prospectus was
deemed part of and included in the registration
statement; and
(b) Each prospectus required to be filed pursuant to
Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration
statement in reliance on Rule 430B relating to an offering
made pursuant to Rule 415(a)(1)(i), (vii), or (x) for
the purpose of providing the information required by
section 10(a) of the Securities Act of 1933 shall be deemed
to be part of and included in the registration statement as of
the earlier of the date such form of prospectus is first used
after effectiveness or the date of the first contract of sale of
securities in the offering described in the prospectus. As
provided in Rule 430B, for liability purposes of the issuer
and any person that is at that date an underwriter, such date
shall be deemed to be a new effective date of the registration
statement relating to the securities in the registration
statement to which that prospectus relates, and the offering of
such securities at that time shall be deemed to be the initial
bona fide offering thereof. Provided, however, that no statement
made in a registration statement or prospectus that is a part of
the registration statement or made in a document incorporated or
deemed incorporated by reference into the registration statement
or prospectus that is a part of the registration statement will,
as to a purchaser with a time of contract of sale prior to such
effective date, supersede or modify any statement that was made
in the registration statement or prospectus that was part of the
registration statement or made in any such document immediately
prior to such effective date; or
(ii) If the registration is subject to Rule 430C, each
prospectus filed pursuant to Rule 424(b) as part of a
registration statement relating to an offering, other than
registration statement relying on Rule 430B or other than
prospectuses filed in reliance on Rule 430A, shall be
deemed to be part of and included in the registration statement
as of the date it is first used after effectiveness. Provided,
however, that no statement made in a registration statement or
prospectus that is part of the registration statement or
prospectus that is part of the registration statement will, as
to a purchaser with a time of contract of sale prior to such
first use, supersede or modify any statement that was made in
the registration statement or
II-2
prospectus that was part of the registration statement or made
in any such document immediately prior to such date of first use.
(5) That, for the purpose of determining liability of the
registrant under the Securities Act of 1933 to any purchaser in
the initial distribution of the securities:
The undersigned registrant undertakes that in a primary offering
of securities of the undersigned registrant pursuant to this
registration statement, regardless of the underwriting method
used to sell the securities to the purchaser, if the securities
are offered or sold to such purchaser by means of any of the
following communications, the undersigned registrant will be a
seller to the purchaser and will be considered to offer or sell
such securities to such purchaser:
(i) any preliminary prospectus or prospectus of the
undersigned registrant relating to the offering required to be
filed pursuant to Rule 424;
(ii) any free writing prospectus relating to the offering
prepared by or on behalf of the undersigned registrant or used
or referred to by the undersigned registrant;
(iii) the portion of any other free writing prospectus
relating to the offering containing material information about
the undersigned registrant or its securities provided by or on
behalf of the undersigned registrant; and
(iv) any other communication that is an offer in the
offering made by the undersigned registrant to the purchaser.
The undersigned registrant hereby undertakes that, for purposes
of determining any liability under the Securities Act of 1933,
each filing of the registrants annual report pursuant to
Section 13(a) or Section 15(d) of the Securities
Exchange Act of 1934 (and, where applicable, each filing of an
employee benefit plans annual report pursuant to
Section 15(d) of the Securities Exchange Act of
1934) that is incorporated by reference in the registration
statement shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of
such securities at that time shall be deemed to be the initial
bona fide offering thereof.
Insofar as indemnification for liabilities arising under the
Securities Act of 1933 may be permitted to directors,
officers and controlling persons of the registrant pursuant to
the foregoing provisions, or otherwise, the registrant has been
advised that in the opinion of the Securities and Exchange
Commission such indemnification is against public policy as
expressed in the Act and is, therefore, unenforceable. In the
event that a claim for indemnification against such liabilities
(other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the
registrant in the successful defense of any action, suit or
proceeding) is asserted by such director, officer or controlling
person in connection with the securities being registered, the
registrant will, unless in the opinion of its counsel the matter
has been settled by controlling precedent, submit to a court of
appropriate jurisdiction the question whether such
indemnification by it is against public policy as expressed in
the Securities Act of 1933 and will be governed by the final
adjudication of such issue.
II-3
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the
registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on
Form S-3
and has duly caused this registration statement to be signed on
its behalf by the undersigned, thereunto duly authorized, in the
City of Sydney, Australia, on this 19th day of March, 2008.
MARSHALL EDWARDS, INC.
|
|
|
|
By:
|
/s/ Christopher
Naughton
|
Name: Christopher Naughton
|
|
|
|
Title:
|
Chief Executive Officer and President
|
POWER OF
ATTORNEY
Each person whose individual signature appears below hereby
authorizes and appoints Christopher Naughton and David R.
Seaton, and each of them, with full power of substitution and
resubstitution and full power to act without the other, as his
or her true and lawful attorney-in-fact and agent to act in his
or her name, place and stead and to execute in the name and on
behalf of each person, individually and in each capacity stated
below, and to file, any and all amendments to this Registration
Statement, including any and all post-effective amendments and
amendments thereto and any registration statement relating to
the same offering as this Registration Statement that is to be
effective upon filing pursuant to Rule 462(b) under the
Securities Act of 1933, as amended, and to file the same, with
all exhibits thereto, and other documents in connection
therewith, with the Securities and Exchange Commission, granting
unto said attorneys-in-fact and agents, and each of them, full
power and authority to do and perform each and every act and
thing, ratifying and confirming all that said attorneys-in-fact
and agents or either of them or their or his or her substitute
or substitutes may lawfully do or cause to be done by virtue
thereof.
Pursuant to the requirements of the Securities Act of 1933, this
registration statement has been signed by the following persons
in the capacities and on the dates indicated below.
|
|
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
|
/s/ Christopher
Naughton
|
|
Chief Executive Officer and President, Director (Principal
Executive Officer)
|
|
March 19, 2008
|
|
|
|
|
|
/s/ David
R. Seaton
|
|
Chief Financial Officer and Secretary (Principal Financial
Officer and Principal Accounting Officer)
|
|
March 19, 2008
|
|
|
|
|
|
/s/ Philip
A. Johnston
|
|
Director
|
|
March 19, 2008
|
|
|
|
|
|
/s/ Bryan
Williams
|
|
Director
|
|
March 19,2008
|
|
|
|
|
|
/s/ Paul
J. Nestel
|
|
Director
|
|
March 19, 2008
|
|
|
|
|
|
/s/ Stephen
Breckenridge
|
|
Director
|
|
March 19, 2008
|
|
|
|
|
|
/s/ William
D. Rueckert
|
|
Director
|
|
March 19, 2008
|
II-4
EXHIBIT INDEX
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
1
|
.1
|
|
Form of Underwriting Agreement**
|
|
3
|
.1
|
|
Certificate of Designation of Preferred Stock**
|
|
4
|
.1
|
|
Specimen Common Stock Certificate**
|
|
4
|
.2
|
|
Specimen Preferred Stock Certificate**
|
|
4
|
.3
|
|
Specimen Warrant Certificate**
|
|
4
|
.4
|
|
Form of Warrant**
|
|
4
|
.5
|
|
Form of Warrant Agreement**
|
|
5
|
.1
|
|
Opinion of Morgan Lewis & Bockius LLP*
|
|
12
|
.1
|
|
Statement re Computation of Ratios*
|
|
23
|
.1
|
|
Consent of BDO Kendalls (NSW)*
|
|
23
|
.2
|
|
Consent of Morgan Lewis & Bockius LLP (included as
Exhibit 5.1)
|
|
24
|
.1
|
|
Power of Attorney (included on signature page)
|
|
|
|
* |
|
Filed herewith. |
|
** |
|
To be filed by amendment. |
EX-5.1
Exhibit
5.1
March 19, 2008
Marshall Edwards, Inc.
140 Wicks Road
North Ryde NSW 2113
Australia
RE: Marshall Edwards, Inc. Registration
Statement on
Form S-3
Ladies and Gentlemen:
We have acted as counsel to Marshall Edwards, Inc., a Delaware
corporation (the Company), in
connection with the Registration Statement on
Form S-3
(the Registration Statement) under the
Securities Act of 1933, as amended (the Securities
Act) relating to the proposed offer and sale by the
Company, from time to time, as set forth in the prospectus
contained in the Registration Statement (the
Prospectus) and as shall be set forth in one
or more supplements to the Prospectus (each, a
Prospectus Supplement) of up to $75,000,000
aggregate principal amount of the Companys common stock,
par value $0.00000002 per share (the Common
Stock), preferred stock, in one or more classes or
series (the Preferred Stock) and warrants to
purchase the Common Stock and Preferred Stock (the
Warrants, collectively with the Common Stock
and the Preferred Stock, the Securities). The
Company may offer and sell the Securities on a delayed or
continuous basis pursuant to Rule 415 under the Securities
Act.
Warrants will be issued pursuant to a warrant agreement (the
Warrant Agreement) to be entered into between
the Company and a bank or trust company acting as Warrant Agent.
In connection with this opinion letter, we have examined copies
of the Registration Statement and originals, or copies certified
or otherwise identified to our satisfaction, of the Restated
Certificate of Incorporation (the Certificate of
Incorporation) and Amended and Restated By-Laws (the
By-Laws) of the Company and such other
documents, records and other instruments as we have deemed
appropriate for purposes of the opinion set forth herein.
We have assumed the genuineness of all signatures, the legal
capacity of all natural persons, the authenticity of the
documents submitted to us as originals, the conformity with the
originals of all documents submitted to us as certified,
facsimile or photostatic copies and the authenticity of the
originals of all documents submitted to us as copies.
With respect to our opinion as to the Common Stock, we have
assumed that, at the time of issuance and sale, a sufficient
number of shares of Common Stock will be authorized and
available for issuance and that the consideration for the
issuance and sale of the Common Stock (or Preferred Stock
convertible into Common Stock or Warrants exercisable for Common
Stock) will be in an amount that is not less than the par value
of the Common Stock. With respect to our opinion as to the
Preferred Stock, we have assumed that (i) prior to any
issuance or sale of shares of a class or series of Preferred
Stock, an appropriate Certificate of Designations with respect
to such class or series of Preferred Stock will have been duly
authorized by all necessary corporate action on the part of the
Company and filed with the Secretary of State of the State of
Delaware and (ii) at the time of issuance and sale, a
sufficient number of shares of Preferred Stock are authorized,
designated and available for issuance and that the consideration
for the issuance and sale of the Preferred Stock (or Warrants
exercisable for Preferred Stock) will be in an amount that is
not less than the par value of the Preferred Stock. We have also
assumed that any Warrants offered under the Registration
Statement will be executed in the forms filed as exhibits to the
Registration Statement.
Subject to the foregoing and the other matters set forth herein,
it is our opinion that, as of the date hereof:
1. With respect to the Common Stock offered under the
Registration Statement, provided that (i) the Registration
Statement and any required post-effective amendment thereto have
all become effective under the Securities Act and the Prospectus
and any and all Prospectus Supplement(s) required by applicable
laws have been delivered and filed as required by such laws,
(ii) the issuance of the Common Stock has been duly
authorized by all necessary corporate action on the part of the
Company and (iii) the issuance and sale of the Common Stock
do not violate any applicable law, are in conformity with the
Companys Certificate of Incorporation and By-Laws, do not
result in a default under or breach of any agreement or
instrument binding upon the Company, then the Common Stock, when
issued and sold as contemplated in the Registration Statement,
the Prospectus and the related Prospectus Supplement(s) and in
accordance with any applicable duly authorized, executed and
delivered purchase, underwriting or similar agreement, or upon
conversion of any convertible Preferred Stock, in accordance
with its terms, or upon exercise of any Warrant, in accordance
with its terms, will be duly authorized, validly issued, fully
paid and nonassessable.
2. With respect to the Preferred Stock offered under the
Registration Statement, provided that (i) the Registration
Statement and any required post-effective amendment thereto have
all become effective under the Securities Act and the Prospectus
and any and all Prospectus Supplement(s) required by applicable
laws have been delivered and filed as required by such laws,
(ii) the terms and issuance of the Preferred Stock have
been duly authorized by all necessary corporate action on the
part of the Company and (iii) the terms of the shares of
Preferred Stock and their issuance and sale do not violate any
applicable law, are in conformity with the Certificate of
Incorporation and By-Laws and do not result in a default under
or breach of any agreement or instrument binding upon the
Company, then the Preferred Stock, when issued and sold as
contemplated in the Registration Statement, the Prospectus and
the related Prospectus Supplement(s) and in accordance with any
applicable duly authorized, executed and delivered purchase,
underwriting or similar agreement, or upon exercise of any
Warrant in accordance with its terms, will be duly authorized,
validly issued, fully paid and nonassessable.
3. With respect to the Warrants issued under the Warrant
Agreement and offered under the Registration Statement, provided
that (i) the Registration Statement and any required
post-effective amendment thereto have all become effective under
the Securities Act and the Prospectus and any and all Prospectus
Supplement(s) required by applicable laws have been delivered
and filed as required by such laws, (ii) the Warrant
Agreement has been duly authorized by the Company and the
Warrant Agent by all necessary corporate action, (iii) the
Warrant Agreement has been duly executed and delivered by the
Company and the Warrant Agent, (iv) the issuance and terms
of the Warrants have been duly authorized by the Company by all
necessary corporate action and (v) the terms of the
Warrants and of their issuance and sale have been duly
established in conformity with the Warrant Agreement and as
described in the Registration Statement, the Prospectus and the
related Prospectus Supplement(s), so as to be in conformity with
the Certificate of Incorporation and By-Laws and so as not to
violate any applicable law or result in a default under or
breach of any agreement or instrument binding upon the Company,
then the Warrants, when issued and sold in accordance with the
Warrant Agreement and a duly authorized, executed and delivered
purchase, underwriting or similar agreement, will be valid and
legally binding obligations of the Company, enforceable against
the Company in accordance with their terms, except as
enforcement thereof may be limited by applicable bankruptcy,
insolvency, reorganization, arrangement, moratorium or other
similar laws affecting creditors rights, and subject to
general equity principles and to limitations on availability of
equitable relief, including specific performance.
We assume for purposes of this opinion that (i) the Warrant
Agent is duly organized, validly existing and in good standing
under the laws of its jurisdiction of organization,
(ii) the Warrant Agent is duly qualified to engage in the
activities contemplated by the Warrant Agreement, (iii) the
Warrant Agent is in compliance, generally and with respect to
acting as a Warrant Agent under the Warrant Agreement, with all
applicable laws and regulations and (iv) the Warrant Agent
has the requisite organizational and legal power and authority
to perform its obligations under the Warrant Agreement.
The foregoing opinions are limited to the federal laws of the
United States and the laws of the State of Delaware.
The opinion letter is limited to the matters stated herein and
no opinions may be implied or inferred beyond that matters
expressly stated herein. The opinions expressed herein are as of
the date hereof and we assume no obligation to update or
supplement such opinions to reflect any facts or circumstances
that may hereafter come to our attention or any changes in the
law that may hereafter occur.
This opinion letter is rendered only to the Company in
connection with the offer and sale of the Securities while this
Registration Statement is in effect. This opinion may not be
relied upon by the Company for any other purpose or furnished
to, quoted to or relied upon by any other person, firm or
corporation for any purpose.
We consent to your filing this opinion letter as an exhibit to
the Registration Statement and to the reference to our firm
under the caption Legal Matters in the prospectus
included therein. In giving such opinion, we do not hereby admit
that we are acting within the category of persons whose consent
is required under Section 7 of the Securities Act or the
rules or regulations of the U.S. Securities and Exchange
Commission thereunder.
Very truly yours,
/s/ Morgan
Lewis & Bockius LLP
Morgan Lewis & Bockius LLP
EX-12.1
Exhibit 12.1
Statement
re Computation of Ratios
We did not have any earnings or fixed charges for the six months
ended December 31, 2007 or the years ended June 30,
2007, 2006, 2005, 2004 and 2003. We also did not have any shares
of preferred stock outstanding during these periods.
EX-23.1
Exhibit
23.1
|
|
|
|
|
|
|
|
|
BDO Kendalls (NSW)
Level 19, 2 Market St
Sydney NSW 2000
GPO Box 2551
Sydney NSW 2001
Phone 61 2 9286 5555
Fax 61 2 9286 5599
info.sydney@bdo.com.au
www.bdo.com.au
|
|
|
|
|
|
|
|
|
|
ABN 57 908 209 104
|
Marshall Edwards, Inc.
140 Wicks Road
NORTH RYDE NSW 2113
AUSTRALIA
CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the
Prospectus constituting a part of this Registration Statement of
our report dated September 27, 2007, relating to the
consolidated financial statements appearing in the
Companys Annual Report on
Form 10-K
for the year ended June 30, 2007.
We also consent to the reference to us under the caption
Experts in the Prospectus.
BDO Kendalls (NSW)
Sydney, NSW, Australia
March 19, 2008
BDO Kendalls is a national association
of separate partnerships and entitles.
Liability limited by a scheme approved
under Professional Standards Legislation